STI 9167
Alternative Names: COVISHIELD - Sorrento Therapeutics; COVISHIELD antibody - Sorrento Therapeutics; STI-9167; STI-9199Latest Information Update: 28 Jun 2024
At a glance
- Originator Mount Sinai Health System
- Developer Sorrento Therapeutics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (IV)
- 28 Jun 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (IV)
- 13 Feb 2023 Sorrento Therapeutics withdraws a phase II trial for COVID-2019 infections (In adolescents, In adults, In the elderly) prior to enrolment in USA (Intranasal,Liquid) (NCT05372783)